Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Stock Competitors & Peer Comparison

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, VRTX has a market cap of 128.1B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while VRTX trades at $504.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas VRTX's P/E ratio is 26.52. In terms of profitability, ALNY's ROE is +0.94%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ALNY is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check VRTX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, REGN has a market cap of 75.7B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while REGN trades at $735.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas REGN's P/E ratio is 16.11. In terms of profitability, ALNY's ROE is +0.94%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ALNY is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check REGN's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, MRNA has a market cap of 75.4B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while MRNA trades at $190.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas MRNA's P/E ratio is -23.31. In terms of profitability, ALNY's ROE is +0.94%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ALNY is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check MRNA's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ALNY's ROE is +0.94%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, ALNY is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check VRNA's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ARGX has a market cap of 57.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ARGX trades at $919.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ARGX's P/E ratio is 33.14. In terms of profitability, ALNY's ROE is +0.94%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, ALNY is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ARGX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, RVMDW has a market cap of 45.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while RVMDW trades at $11.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas RVMDW's P/E ratio is -1.31. In terms of profitability, ALNY's ROE is +0.94%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ALNY is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RVMDW's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, RVMD has a market cap of 43.9B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while RVMD trades at $206.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas RVMD's P/E ratio is -23.43. In terms of profitability, ALNY's ROE is +0.94%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ALNY is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RVMD's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ALNY's ROE is +0.94%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ALNY is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check SGEN's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ONC has a market cap of 38.3B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ONC trades at $358.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ONC's P/E ratio is 63.04. In terms of profitability, ALNY's ROE is +0.94%, compared to ONC's ROE of +0.14%. Regarding short-term risk, ALNY is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ONC's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ROIV has a market cap of 25.8B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ROIV trades at $35.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ROIV's P/E ratio is -33.98. In terms of profitability, ALNY's ROE is +0.94%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ALNY is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ROIV's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while BNTX trades at $96.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas BNTX's P/E ratio is -12.57. In terms of profitability, ALNY's ROE is +0.94%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ALNY is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BNTX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, INSM has a market cap of 24.1B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while INSM trades at $111.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas INSM's P/E ratio is -27.04. In terms of profitability, ALNY's ROE is +0.94%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ALNY is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check INSM's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, INCY has a market cap of 23.4B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while INCY trades at $115.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas INCY's P/E ratio is 15.50. In terms of profitability, ALNY's ROE is +0.94%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ALNY is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check INCY's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, UTHR has a market cap of 23B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while UTHR trades at $541.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas UTHR's P/E ratio is 19.38. In terms of profitability, ALNY's ROE is +0.94%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ALNY is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check UTHR's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while GMAB trades at $34.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas GMAB's P/E ratio is 26.19. In terms of profitability, ALNY's ROE is +0.94%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ALNY is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check GMAB's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ALNY's ROE is +0.94%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ALNY is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BGNE's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ALNY's ROE is +0.94%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ALNY is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check DNA-WT's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, JAZZ has a market cap of 14.8B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while JAZZ trades at $235.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas JAZZ's P/E ratio is 8.79. In terms of profitability, ALNY's ROE is +0.94%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ALNY is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check JAZZ's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while EXEL trades at $58.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas EXEL's P/E ratio is 16.68. In terms of profitability, ALNY's ROE is +0.94%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ALNY is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check EXEL's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, NBIX has a market cap of 14.4B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while NBIX trades at $143.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas NBIX's P/E ratio is 20.69. In terms of profitability, ALNY's ROE is +0.94%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ALNY is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check NBIX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ASND trades at $227.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ASND's P/E ratio is -94.16. In terms of profitability, ALNY's ROE is +0.94%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ALNY is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ASND's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, SMMT has a market cap of 13.4B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while SMMT trades at $16.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas SMMT's P/E ratio is -14.96. In terms of profitability, ALNY's ROE is +0.94%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ALNY is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check SMMT's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while BBIO trades at $67.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas BBIO's P/E ratio is -17.98. In terms of profitability, ALNY's ROE is +0.94%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ALNY is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BBIO's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while HALO trades at $109.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas HALO's P/E ratio is 19.95. In terms of profitability, ALNY's ROE is +0.94%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ALNY is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check HALO's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ALNY's ROE is +0.94%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ALNY is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check KRTX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, TXG has a market cap of 11.9B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while TXG trades at $93.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas TXG's P/E ratio is -158.47. In terms of profitability, ALNY's ROE is +0.94%, compared to TXG's ROE of -0.09%. Regarding short-term risk, ALNY is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check TXG's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, TWST has a market cap of 11.7B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while TWST trades at $188.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas TWST's P/E ratio is -84.99. In terms of profitability, ALNY's ROE is +0.94%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ALNY is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check TWST's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, MDGL has a market cap of 11.5B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while MDGL trades at $499.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas MDGL's P/E ratio is -39.02. In terms of profitability, ALNY's ROE is +0.94%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ALNY is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check MDGL's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while TECH trades at $72.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas TECH's P/E ratio is 37.32. In terms of profitability, ALNY's ROE is +0.94%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ALNY is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check TECH's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ALNY's ROE is +0.94%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ALNY is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RNAM's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while BMRN trades at $57.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas BMRN's P/E ratio is 27.49. In terms of profitability, ALNY's ROE is +0.94%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ALNY is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BMRN's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, IBRX has a market cap of 10.8B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while IBRX trades at $10.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas IBRX's P/E ratio is -10.60. In terms of profitability, ALNY's ROE is +0.94%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ALNY is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check IBRX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ALNY's ROE is +0.94%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ALNY is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RXDX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, KRYS has a market cap of 9.5B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while KRYS trades at $322.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas KRYS's P/E ratio is 40.39. In terms of profitability, ALNY's ROE is +0.94%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ALNY is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check KRYS's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, AXSM has a market cap of 9.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while AXSM trades at $179.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas AXSM's P/E ratio is -46.80. In terms of profitability, ALNY's ROE is +0.94%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ALNY is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check AXSM's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ALNY's ROE is +0.94%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ALNY is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check NUVL's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ARWR has a market cap of 9B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ARWR trades at $64.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ARWR's P/E ratio is -28.53. In terms of profitability, ALNY's ROE is +0.94%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ALNY is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ARWR's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, PTGX has a market cap of 9B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while PTGX trades at $140.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas PTGX's P/E ratio is 135.98. In terms of profitability, ALNY's ROE is +0.94%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ALNY is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check PTGX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ALNY's ROE is +0.94%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ALNY is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CRNX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, KYMR has a market cap of 8.8B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while KYMR trades at $107.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas KYMR's P/E ratio is -33.56. In terms of profitability, ALNY's ROE is +0.94%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ALNY is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check KYMR's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ALNY's ROE is +0.94%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ALNY is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check IMGN's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ALNY's ROE is +0.94%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ALNY is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BPMC's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas APGE's P/E ratio is -31.19. In terms of profitability, ALNY's ROE is +0.94%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ALNY is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check APGE's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while TGTX trades at $54.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas TGTX's P/E ratio is 19.67. In terms of profitability, ALNY's ROE is +0.94%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ALNY is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check TGTX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, PRAX has a market cap of 8.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while PRAX trades at $295.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas PRAX's P/E ratio is -22.85. In terms of profitability, ALNY's ROE is +0.94%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ALNY is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check PRAX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas CERE's P/E ratio is -16.47. In terms of profitability, ALNY's ROE is +0.94%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ALNY is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CERE's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while CYTK trades at $65.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas CYTK's P/E ratio is -9.09. In terms of profitability, ALNY's ROE is +0.94%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ALNY is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CYTK's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while PCVX trades at $56.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas PCVX's P/E ratio is -7.40. In terms of profitability, ALNY's ROE is +0.94%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ALNY is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check PCVX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, SYRE has a market cap of 8.1B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while SYRE trades at $93.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas SYRE's P/E ratio is -47.79. In terms of profitability, ALNY's ROE is +0.94%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ALNY is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check SYRE's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, CAI has a market cap of 8B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while CAI trades at $28.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas CAI's P/E ratio is 79.52. In terms of profitability, ALNY's ROE is +0.94%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ALNY is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CAI's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ALNY's ROE is +0.94%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ALNY is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check MTSR's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, IONS has a market cap of 7.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while IONS trades at $43.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas IONS's P/E ratio is -13.31. In terms of profitability, ALNY's ROE is +0.94%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ALNY is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check IONS's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while IMVT trades at $33.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas IMVT's P/E ratio is -11.92. In terms of profitability, ALNY's ROE is +0.94%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ALNY is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check IMVT's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ALNY's ROE is +0.94%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ALNY is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check MRUS's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ABVX has a market cap of 6.8B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ABVX trades at $92.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ABVX's P/E ratio is -15.22. In terms of profitability, ALNY's ROE is +0.94%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, ALNY is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ABVX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ALNY's ROE is +0.94%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ALNY is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ACLX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas RETA's P/E ratio is -66.29. In terms of profitability, ALNY's ROE is +0.94%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ALNY is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RETA's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while BLTE trades at $159.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas BLTE's P/E ratio is -85.33. In terms of profitability, ALNY's ROE is +0.94%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ALNY is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BLTE's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while RYTM trades at $92.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas RYTM's P/E ratio is -29.85. In terms of profitability, ALNY's ROE is +0.94%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ALNY is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RYTM's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, IOVA has a market cap of 6.3B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while IOVA trades at $14.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas IOVA's P/E ratio is -19.47. In terms of profitability, ALNY's ROE is +0.94%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, ALNY is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check IOVA's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ALNY's ROE is +0.94%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ALNY is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CNTA's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while LGND trades at $302.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas LGND's P/E ratio is 33.26. In terms of profitability, ALNY's ROE is +0.94%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ALNY is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check LGND's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while CGON trades at $67.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas CGON's P/E ratio is -25.05. In terms of profitability, ALNY's ROE is +0.94%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ALNY is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CGON's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, KOD has a market cap of 5.9B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while KOD trades at $94.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas KOD's P/E ratio is -22.65. In terms of profitability, ALNY's ROE is +0.94%, compared to KOD's ROE of -2.73%. Regarding short-term risk, ALNY is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check KOD's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ALNY's ROE is +0.94%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, ALNY is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CDTX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while SRRK trades at $46.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas SRRK's P/E ratio is -13.57. In terms of profitability, ALNY's ROE is +0.94%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ALNY is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check SRRK's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ALNY's ROE is +0.94%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ALNY is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ABCM's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ALNY's ROE is +0.94%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ALNY is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ISEE's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while CRSP trades at $55.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas CRSP's P/E ratio is -11.64. In terms of profitability, ALNY's ROE is +0.94%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ALNY is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check CRSP's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, COGT has a market cap of 5.3B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while COGT trades at $31.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas COGT's P/E ratio is -14.70. In terms of profitability, ALNY's ROE is +0.94%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ALNY is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check COGT's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while PTCT trades at $63.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas PTCT's P/E ratio is -27.24. In terms of profitability, ALNY's ROE is +0.94%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ALNY is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check PTCT's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while TVTX trades at $56.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas TVTX's P/E ratio is -126.51. In terms of profitability, ALNY's ROE is +0.94%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ALNY is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check TVTX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas APLS's P/E ratio is 38.35. In terms of profitability, ALNY's ROE is +0.94%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ALNY is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check APLS's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ERAS trades at $14.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ERAS's P/E ratio is -15.85. In terms of profitability, ALNY's ROE is +0.94%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ALNY is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ERAS's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ORKA has a market cap of 5.1B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ORKA trades at $84.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ORKA's P/E ratio is -43.57. In terms of profitability, ALNY's ROE is +0.94%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ALNY is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ORKA's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, MIRM has a market cap of 5.1B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while MIRM trades at $82.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas MIRM's P/E ratio is -5.70. In terms of profitability, ALNY's ROE is +0.94%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ALNY is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check MIRM's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while DFTX trades at $37.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas DFTX's P/E ratio is N/A. In terms of profitability, ALNY's ROE is +0.94%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ALNY is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check DFTX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, DNTH has a market cap of 4.9B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while DNTH trades at $88.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas DNTH's P/E ratio is -21.26. In terms of profitability, ALNY's ROE is +0.94%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ALNY is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check DNTH's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while MANE trades at $116.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas MANE's P/E ratio is -37.17. In terms of profitability, ALNY's ROE is +0.94%, compared to MANE's ROE of -0.38%. Regarding short-term risk, ALNY is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check MANE's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas TERN's P/E ratio is -51.41. In terms of profitability, ALNY's ROE is +0.94%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ALNY is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check TERN's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ALNY's ROE is +0.94%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ALNY is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check FOLD's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ADPT trades at $28.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ADPT's P/E ratio is -69.15. In terms of profitability, ALNY's ROE is +0.94%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ALNY is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ADPT's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ALNY's ROE is +0.94%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ALNY is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check AKRO's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ALNY's ROE is +0.94%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ALNY is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ALPN's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while EWTX trades at $41.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas EWTX's P/E ratio is -22.38. In terms of profitability, ALNY's ROE is +0.94%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ALNY is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check EWTX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas OPT's P/E ratio is -1.52. In terms of profitability, ALNY's ROE is +0.94%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ALNY is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check OPT's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ALNY's ROE is +0.94%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ALNY is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check PRTC's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, ABCL has a market cap of 4.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while ABCL trades at $13.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas ABCL's P/E ratio is -25.44. In terms of profitability, ALNY's ROE is +0.94%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, ALNY is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ABCL's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while RLAY trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas RLAY's P/E ratio is -12.08. In terms of profitability, ALNY's ROE is +0.94%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ALNY is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RLAY's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ALNY's ROE is +0.94%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ALNY is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check MRTX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas CPRX's P/E ratio is 17.49. In terms of profitability, ALNY's ROE is +0.94%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ALNY is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CPRX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while TNGX trades at $23.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas TNGX's P/E ratio is -28.00. In terms of profitability, ALNY's ROE is +0.94%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, ALNY is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check TNGX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ALNY's ROE is +0.94%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ALNY is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RYZB's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ALNY's ROE is +0.94%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ALNY is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CBAY's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, XENE has a market cap of 3.7B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while XENE trades at $38.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas XENE's P/E ratio is -8.09. In terms of profitability, ALNY's ROE is +0.94%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ALNY is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check XENE's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while TLX trades at $10.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas TLX's P/E ratio is 110.13. In terms of profitability, ALNY's ROE is +0.94%, compared to TLX's ROE of +0.07%. Regarding short-term risk, ALNY is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check TLX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, IDYA has a market cap of 3.6B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while IDYA trades at $37.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas IDYA's P/E ratio is -19.26. In terms of profitability, ALNY's ROE is +0.94%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, ALNY is more volatile compared to IDYA. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check IDYA's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ALNY's ROE is +0.94%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ALNY is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check SWTX's competition here

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALNY stands at 29.4B. In comparison, PBLS has a market cap of 3.5B. Regarding current trading prices, ALNY is priced at $219.72 on the NASDAQ, while PBLS trades at $30.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALNY currently has a P/E ratio of 39.59, whereas PBLS's P/E ratio is -16.11. In terms of profitability, ALNY's ROE is +0.94%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, ALNY is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check PBLS's competition here